Achieve Life Sciences (ACHV) to Release Earnings on Thursday

Achieve Life Sciences (NASDAQ:ACHV) is expected to be announcing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:30 AM ET.

Achieve Life Sciences (NASDAQ:ACHV) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.37). On average, analysts expect Achieve Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Achieve Life Sciences Trading Up 3.6%

NASDAQ ACHV opened at $4.95 on Thursday. The stock has a market cap of $252.97 million, a P/E ratio of -3.39 and a beta of 1.58. The company has a current ratio of 6.64, a quick ratio of 6.64 and a debt-to-equity ratio of 0.21. The company has a fifty day simple moving average of $3.39 and a two-hundred day simple moving average of $2.99. Achieve Life Sciences has a 12-month low of $1.84 and a 12-month high of $5.78.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Achieve Life Sciences in a research note on Wednesday, October 8th. HC Wainwright initiated coverage on shares of Achieve Life Sciences in a report on Thursday, August 21st. They issued a “buy” rating and a $12.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $12.00.

Insider Activity at Achieve Life Sciences

In related news, Director Thomas Braxton King sold 139,858 shares of the company’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $2.77, for a total transaction of $387,406.66. Following the completion of the sale, the director owned 315,142 shares of the company’s stock, valued at approximately $872,943.34. This represents a 30.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Richard Alistair Stewart sold 129,501 shares of the company’s stock in a transaction that occurred on Thursday, September 18th. The shares were sold at an average price of $2.92, for a total value of $378,142.92. Following the completion of the sale, the chief executive officer owned 228,875 shares of the company’s stock, valued at $668,315. This trade represents a 36.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 381,972 shares of company stock worth $1,084,997 in the last 90 days. 3.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE grew its holdings in shares of Achieve Life Sciences by 39.9% during the 2nd quarter. Bank of America Corp DE now owns 33,731 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 9,617 shares during the period. AQR Capital Management LLC purchased a new position in Achieve Life Sciences in the 1st quarter valued at approximately $32,000. Sender Co & Partners Inc. purchased a new position in Achieve Life Sciences in the second quarter valued at $56,000. Shay Capital LLC boosted its stake in shares of Achieve Life Sciences by 10.1% in the 2nd quarter. Shay Capital LLC now owns 292,647 shares of the biopharmaceutical company’s stock valued at $661,000 after buying an additional 26,913 shares during the period. Finally, Brevan Howard Capital Management LP purchased a new position in Achieve Life Sciences in the second quarter worth approximately $145,000. 33.52% of the stock is currently owned by hedge funds and other institutional investors.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.